Member access

4-Traders Homepage  >  Shares  >  Euronext Paris  >  SANOFI    SAN   FR0000120578

SANOFI (SAN)

2574
SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Sanofi: Tests Show Zaltrap Improves Colorectal Cancer Survival Rate

10/08/2012 | 01:44am US/Eastern

French drug company Sanofi SA (>> SANOFI) Monday said results from the pivotal Phase III Velour study evaluating Zaltrap showed improvement in overall survival rate to colorectal cancer.

MAIN FACTS:

- Sanofi said the Journal of Clinical Oncology published the results of the study evaluating Zaltrap effects.

- In the Velour trial evaluating metastatic colorectal cancer patients previously treated with an oxaliplatin-containing regimen, Zaltrap in combination with the Folfiri chemotherapy regimen (5-fluorouracil, leucovorin, irinotecan) showed a statistically significant improvement in overall survival, progression-free survival, and the overall tumor response rate versus placebo plus Folfiri.

- The Velour data supported the regulatory approval of Zaltrap by the U.S. Food and Drug Administration (FDA) on August 3, 2012 after a Priority Review.

- Zaltrap is under review at the European Medicines Agency and other regulatory agencies worldwide, Sanofi says.

-Write to Inti Landauro at inti.landauro@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : SANOFI
React to this article
Latest news on SANOFI
01/30 SANOFI : 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana..
01/30 SANOFI : Pasteur Provides Significant Donation to East Stroudsburg Salvation Arm..
01/30DJNovo Nordisk to Benefit From Dollar Strength in 2015
01/30 Three months on, fruitless CEO search overshadows Sanofi
01/29 SANOFI : art exhibition of 'Life and Hope'
01/28 SANOFI : New Findings from Sanofi Pasteur Update Understanding of Streptococcal ..
01/28 SANOFI : INVESTOR ALERT: Law Offices of Howard G. Smith Announces Lead Plaintiff..
01/27DJAmgen Profit Rises 27% on Higher Sales of Key Drugs -- Update
01/27 SANOFI : and Regeneron Announce Praluent (alirocumab) Biologics License Applicat..
01/27 Baiyunshan, Siemens to March into Medical Devices
Advertisement
Chart
Duration : Period :
SANOFI Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF